<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcdermatol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Dermatology - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcdermatol/</link>
        <description>The latest research articles published by BMC Dermatology</description>
        <dc:date>2009-05-29T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/9/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/8/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/8/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/8/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/8/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-5945/8/1" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/5">
        <title>HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study</title>
        <description>Background:
The influence of streptococcal infections in the pathogenesis of psoriasis is not yet understood. In vitro data suggest that streptococcal factors influence T-cell function in psoriasis in a HLA-dependent manner, but studies designed to measure the HLA-C/Streptococci interaction are lacking. In the present study, we hypothesized that there is a statistical interaction between the result of streptococcal throat cultures and the presence of the HLA-Cw*0602 allele in psoriasis patients.
Methods:
We performed a case control study using the &quot;Stockholm Psoriasis Cohort&quot; consisting of patients consecutively recruited within 12 months of disease onset (Plaque psoriasis = 439, Guttate psoriasis = 143), matched to healthy controls (n = 454) randomly chosen from the Swedish Population Registry. All individuals underwent physical examination including throat swabs and DNA isolation for HLA-Cw*0602 genotyping.The prevalence of positive streptococcal throat swabs and HLA-Cw*0602 was compared between patients and controls and expressed as odds ratios with 95% confidence intervals. Associations were evaluated separately for guttate and plaque psoriasis by Fisher&apos;s exact test.
Results:
Regardless of disease phenotype, the prevalence of positive streptococcal throat swabs in HLA-Cw*0602 positive patients was twice the prevalence among HLA-Cw*0602 negative patients (OR = 5.8 C.I. = 3.57&#8211;9.67, p &lt; 0.001), while no difference was observed among Cw*0602 positive versus negative controls.The corresponding odds ratios for the guttate and plaque psoriasis phenotypes were 3.5 (CI = 1.5&#8211;8.7, p = 0.01) and 2.3 (CI = 1.0&#8211;5.1, p = 0.02) respectively.
Conclusion:
These findings suggest that among HLA-Cw*0602 positive psoriasis patients, streptococci may contribute to the onset or exacerbation of the inflammatory process independent of the disease phenotype. However, studies on the functional interaction between HLA-C and streptococcal factors are needed.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/5</link>
                <dc:creator>Lotus Mallbris</dc:creator>
                <dc:creator>Katarina Wolk</dc:creator>
                <dc:creator>Fabio Sanchez</dc:creator>
                <dc:creator>Mona Stahle</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:5</dc:source>
        <dc:date>2009-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-5</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/4">
        <title>Prevalence and characteristics of aquagenic pruritus in a young
African population
</title>
        <description>Background:
Aquagenic pruritus (AP) occurs during or after contact of the skin with water such as occurs in bathing.
Methods:
This study aims to describe the prevalence of aquagenic pruritus in a young adult population and describe the circumstances of bathing.A Population-based cross sectional study involving administration of Questionnaires to young adult Nigerians on the occurrence of pruritus associated with bathing.
Results:
The prevalence of bathing pruritus among respondents in this study was 23.8%. The commonest type of water respondents itch to was rain water (23%) followed by cold water (19%). 8.33% of respondents feels like avoiding bathing because of these.
Conclusion:
Bathing pruritus is a common finding among young adult Nigerians in the general population.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/4</link>
                <dc:creator>T Salami</dc:creator>
                <dc:creator>S Samuel</dc:creator>
                <dc:creator>K Eze</dc:creator>
                <dc:creator>E Irekpita</dc:creator>
                <dc:creator>O Oziegbe</dc:creator>
                <dc:creator>M Momoh</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:4</dc:source>
        <dc:date>2009-04-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-4</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-04-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/3">
        <title>Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection</title>
        <description>Background:
Herpes simplex virus infection (HSV) is a common and ubiquitous infection of the skin which causes mucocutaneous lesions called cold sores (herpes labialis) or fever blisters. It is estimated that approximately 80% of the population worldwide are carriers of the Herpes simplex virus, approximately 40% suffer from recurrent recurrent infections. This study evaluates the in vitro skin permeation and penetration of penciclovir and acyclovir from commercialized creams for the treatment of herpes labialis (cold sores), using non viable excised human abdominal skin samples, which were exposed to 5 mg/cm2 of acyclovir 5% cream or penciclovir 1% cream.
Methods:
After 24 h of cream application, excess cream was washed off and layers of stratum corneum were removed by successive tape stripping. Amounts of active ingredients having penetrated through the skin were measured, as well as the amounts in the washed-off cream, in skin strips and creams remaining in the skin. Molecular modelling was used to evaluate physico-chemical differences between the drugs. Western blot analysis enabled to determine whether the marker of basal cells keratin 5 could be detected in the various tape strips.
Results:
Application of penciclovir 1% cream yielded higher concentration of drug in the deeper layers of the epidermis as well as a higher drug flux through the skin. Molecular modelling showed two higher hydrophobic moieties for acyclovir. Presence of the basal cell marker keratin 5 was underscored in the deeper tape strips from the skin, giving evidence that both drugs can reach their target cells.
Conclusion:
Penciclovir 1% cream has the tendency to facilitate the diffusion of the drug through the stratum corneum into the deeper epidermis layers, in which it could reach the target basal cells at effective therapeutical concentration. The small difference in the surface properties between both molecules might also contribute to favour the passage of penciclovir through the epidermis into the deeper basal cells.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/3</link>
                <dc:creator>Nathalie Hasler-Nguyen</dc:creator>
                <dc:creator>Donald Shelton</dc:creator>
                <dc:creator>Gilbert Ponard</dc:creator>
                <dc:creator>Marlene Bader</dc:creator>
                <dc:creator>Martina Schaffrik</dc:creator>
                <dc:creator>Pascal Mallefet</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:3</dc:source>
        <dc:date>2009-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-3</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/2">
        <title>Nonlinear modeling of venous leg ulcer healing rates</title>
        <description>Background:
The purpose of this manuscript was to determine whether the change in wound surface area over time could be described through nonlinear mathematics.
Methods:
We studied 3,588 serial wound tracings of 338 venous leg ulcers (VLUs) that had been followed during a controlled, prospective, randomized trial of two topical wound treatments.
Results:
A majority (72%) of VLUs exhibited surface area reduction via an exponential decay model, particularly during the early stages of healing. These results were consistent with the mechanics of wound contraction and epithelial cell proliferation, supported by the higher frequency at which exponential surface area reduction associated with full wound closure (35% of wounds that fit the exponential model healed vs. 21% of wounds that did not fit the exponential model completely healed during the study period, p = 0.018). Goodness-of-fit statistics suggested that much of the individual variation in healing could be described as nonlinear variation from the exponential model.
Conclusion:
We believe that parameter estimates from a mathematical model may provide a more accurate quantification of wound healing rates, and that similar models may someday reach routine use in comparing the efficacy of various treatments in routine practice and in product registration trials.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/2</link>
                <dc:creator>Matthew Cardinal</dc:creator>
                <dc:creator>David Eisenbud</dc:creator>
                <dc:creator>David Armstrong</dc:creator>
                <dc:creator>Tania Phillips</dc:creator>
                <dc:creator>Keith Harding</dc:creator>
                <dc:creator>Jonathan Mansbridge</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:2</dc:source>
        <dc:date>2009-03-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-2</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-03-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/9/1">
        <title>Mutation analysis of the Gadd45 gene at exon 4 in atypical fibroxanthoma</title>
        <description>Background:
Atypical fibroxanthoma (AFX) histologically mimics high-grade sarcoma in the skin, although it follows a benign clinical course. AFX occurs in the sun-exposed skin and for this reason, an association with ultraviolet light has long been suspected. Bax and Gadd45 are p53 effector proteins. Bax is a programmed cell death protein and belongs to the Bcl-2 family. Gadd45 is a multifunctional DNA damage-inducible gene associated with the process of DNA damage.
Methods:
Immunohistochemical expression of Bax was analyzed in 7 cases of AFX, and in 7 cases of benign fibrous histiocytoma (BFH) used as a comparison. The expression pattern of Bax was compared to previously reported p53 and Gadd45 expressions in a correspondent series. Mutation of the Gadd45 gene at exon 4 was also analyzed in AFX.
Results:
AFX and BFH showed immunoreactivities respectively for Bax (3/7, 0/7), Gadd45 (4/7, 1/7) and p53 (2/7, 0/7). There was no exact correlation between p53 expression and Bax or Gadd45 expression. However, the pattern of expression between Bax and Gadd45 was also the same, with the exception of one case. No mutation of the Gadd45 gene at exon 4 was observed in a series of 6 AFX cases where DNA was available (0/6).
Conclusion:
These results suggest a possible association between Bax and Gadd45 in AFX, and may refute any possibility of dysfunction of Gadd45 in terms of gene mutation, at least at exon 4 of the Gadd45 gene.</description>
        <link>http://www.biomedcentral.com/1471-5945/9/1</link>
                <dc:creator>Akio Sakamoto</dc:creator>
                <dc:creator>Shizuka Akieda</dc:creator>
                <dc:creator>Yoshinao Oda</dc:creator>
                <dc:creator>Yukihide Iwamoto</dc:creator>
                <dc:creator>Masazumi Tsuneyoshi</dc:creator>
                <dc:source>BMC Dermatology 2009, 9:1</dc:source>
        <dc:date>2009-01-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-9-1</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2009-01-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/8/5">
        <title>Dermatitis associated with exposure to a marine cyanobacterium during recreational water exposure</title>
        <description>Background:
Anecdotal evidence reported an outbreak of symptoms on Fraser Island during the late 1990s similar to those expected from exposure to dermotoxins found in the cyanobacterium L. majuscula. This coincided with the presence of a bloom of L. majuscula.
Methods:
Records from the Fraser Island National Parks First aid station were examined. Information on cyanobacterial blooms at Fraser Island were obtained from Queensland National Parks rangers.
Results:
Examination of first aid records from Fraser Island revealed an outbreak of symptoms predominantly in January and February 1998.
Conclusion:
During a bloom of L. majuscula there were numerous reports of symptoms that could be attributed to dermotoxins found in L. majuscula. The other four years examined had no L. majuscula blooms and the number of L. majuscula symptoms was much reduced. These cases comprised a high percentage of the cases treated at the first aid station.</description>
        <link>http://www.biomedcentral.com/1471-5945/8/5</link>
                <dc:creator>Nicholas Osborne</dc:creator>
                <dc:creator>Glen Shaw</dc:creator>
                <dc:source>BMC Dermatology 2008, 8:5</dc:source>
        <dc:date>2008-12-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-8-5</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2008-12-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/8/4">
        <title>Assessment of a new questionnaire for self-reported sun sensitivity in an occupational skin cancer screening program</title>
        <description>Background:
Sun sensitivity of the skin is a risk factor for the development of cutaneous melanoma and other skin cancers. Epidemiological studies on causal factors for the development of melanoma must control for sun sensitivity as a confounder. A standardized instrument for measuring sun sensitivity has not been established yet. It is assumed that many studies show a high potential of residual confounding for sun sensitivity. In the present study, a new questionnaire for the assessment of self-reported sun sensitivity is administered and examined.
Methods:
Prior to an occupational skin cancer screening program, the 745 participating employees were asked to fill in a questionnaire for self-assessment of sun sensitivity. The questionnaire was developed by experts of the working group &quot;Round Table Sunbeds&quot; (RTS) to limit the health hazards of sunbed use in Germany. A sun sensitivity score (RTS-score) was calculated using 10 indicators. The internal consistency of the questionnaire and the agreement with other methods (convergent validity) were examined.
Results:
The RTS-score was calculated for 655 study participants who were 18 to 65 years of age. The correlation of the items among each other was between 0.12 and 0.62. The items and the RTS-score correlated between 0.46 and 0.77. The internal consistency showed a reliability coefficient with 0.82 (Cronbach&apos;s alpha). The comparison with the Fitzpatrick classification, the prevailing standard, was possible in 617 cases with a rank correlation of rs = 0.65. The categorization of the RTS-score in four risk groups showed correct classification to the four skin types of Fitzpatrick in 75% of the cases. Other methods for the assessment of sun sensitivity displayed varying agreements with the RTS-score.
Conclusion:
The RTS questionnaire showed a sufficient internal consistency. There is a good convergent validity between the RTS-score and the Fritzpatrick classification avoiding shortcomings of the prevailing standard. The questionnaire represents a simple, reliable and valid instrument for the assessment of sun sensitivity. The questionnaire can be useful for epidemiological studies as well as for skin cancer prevention. Further development and standardization of sun sensitivity assessments is necessary to strengthen the evidence of epidemiological studies on causal factors of melanoma and other skin cancers.</description>
        <link>http://www.biomedcentral.com/1471-5945/8/4</link>
                <dc:creator>Jurgen Tacke</dc:creator>
                <dc:creator>Jens Dietrich</dc:creator>
                <dc:creator>Beatrix Steinebrunner</dc:creator>
                <dc:creator>Antonius Reifferscheid</dc:creator>
                <dc:source>BMC Dermatology 2008, 8:4</dc:source>
        <dc:date>2008-10-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-8-4</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2008-10-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/8/3">
        <title>Melasma and its association with different types of nevi in women: A case control study

</title>
        <description>Background:
Very little is known about possible association of nevi and melasma. The study objective was to determine if there is an association between melasma and existence of different kinds of nevi.
Methods:
In a case-control study, 120 female melasma patients referred to dermatology clinic of Ardabil and 120 patients referred to other specialty clinics who lacked melasma were enrolled after matching for age. Number of different types of nevi including lentigines and melanocytic nevi were compared between case and control group patients. Data were entered into the computer and analyzed by SPSS 13 statistical software.
Results:
Mean number of lentigines was 25.5 in melasma group compared to 8 in control group(P &lt; 0.01). Mean number of melanocytic nevi was 13.2 in cases compared to 2.8 in control group(P &lt; 0.001). Multivariate analysis showed that existence of freckles, lentigines and more than three melanocytic nevi were positively related to developing melasma. The chance of melasma increased up to 23 times for patients having more than three melanocytic nevi. Congenital nevi were observed among 10% both in case and control groups. Campbell de morgan angiomas were seen among 26 patients(21.8%) in case group compared to 6 patients(5%) in control group.
Conclusion:
Existence of lentigines and melanocytic nevi increases chance of having melasma</description>
        <link>http://www.biomedcentral.com/1471-5945/8/3</link>
                <dc:creator>Hassan Adalatkhah</dc:creator>
                <dc:creator>Homayoun Sadeghi-Bazargani</dc:creator>
                <dc:creator>Nayereh Aminisani</dc:creator>
                <dc:creator>Zeynizade Somayyeh</dc:creator>
                <dc:source>BMC Dermatology 2008, 8:3</dc:source>
        <dc:date>2008-08-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-8-3</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2008-08-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/8/2">
        <title>A systematic review of natural health product treatment for vitiligo</title>
        <description>Background:
Vitiligo is a hypopigmentation disorder affecting 1 to 4% of the world population. Fifty percent of cases appear before the age of 20 years old, and the disfigurement results in psychiatric morbidity in 16 to 35% of those affected.
Methods:
Our objective was to complete a comprehensive, systematic review of the published scientific literature to identify natural health products (NHP) such as vitamins, herbs and other supplements that may have efficacy in the treatment of vitiligo. We searched eight databases including MEDLINE and EMBASE for vitiligo, leucoderma, and various NHP terms. Prospective controlled clinical human trials were identified and assessed for quality.
Results:
Fifteen clinical trials were identified, and organized into four categories based on the NHP used for treatment. 1) L-phenylalanine monotherapy was assessed in one trial, and as an adjuvant to phototherapy in three trials. All reported beneficial effects. 2) Three clinical trials utilized different traditional Chinese medicine products. Although each traditional Chinese medicine trial reported benefit in the active groups, the quality of the trials was poor. 3) Six trials investigated the use of plants in the treatment of vitiligo, four using plants as photosensitizing agents. The studies provide weak evidence that photosensitizing plants can be effective in conjunction with phototherapy, and moderate evidence that Ginkgo biloba monotherapy can be useful for vitiligo. 4) Two clinical trials investigated the use of vitamins in the therapy of vitiligo. One tested oral cobalamin with folic acid, and found no significant improvement over control. Another trial combined vitamin E with phototherapy and reported significantly better repigmentation over phototherapy only. It was not possible to pool the data from any studies for meta-analytic purposes due to the wide difference in outcome measures and poor quality ofreporting.
Conclusion:
Reports investigating the efficacy of NHPs for vitiligo exist, but are of poor methodological quality and contain significant reporting flaws. L-phenylalanine used with phototherapy, and oral Ginkgo biloba as monotherapy show promise and warrant further investigation.</description>
        <link>http://www.biomedcentral.com/1471-5945/8/2</link>
                <dc:creator>Orest Szczurko</dc:creator>
                <dc:creator>Heather Boon</dc:creator>
                <dc:source>BMC Dermatology 2008, 8:2</dc:source>
        <dc:date>2008-05-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-8-2</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2008-05-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-5945/8/1">
        <title>Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model</title>
        <description>Background:
Skin manifestations of Tuberous Sclerosis Complex (TSC) cause significant morbidity. The molecular mechanism underlying TSC is understood and there is evidence that systemic treatment with rapamycin or other mTOR inhibitors may be a useful approach to targeted therapy for the kidney and brain manifestations. Here we investigate topical rapamycin in a mouse model for TSC-related tumors.
Methods:
0.4% and 0.8% rapamycin ointments were applied to nude mice bearing subcutaneous, TSC-related tumors. Topical treatments were compared with injected rapamycin and topical vehicle. Rapamycin levels in blood and tumors were measured to assess systemic drug levels in all cohorts.
Results:
Treatment with topical rapamycin improved survival and reduced tumor growth. Topical rapamycin treatment resulted in systemic drug levels within the known therapeutic range and was not as effective as injected rapamycin.
Conclusion:
Topical rapamycin inhibits TSC-related tumor growth. These findings could lead to a novel treatment approach for facial angiofibromas and other TSC skin lesions.</description>
        <link>http://www.biomedcentral.com/1471-5945/8/1</link>
                <dc:creator>Aubrey Rauktys</dc:creator>
                <dc:creator>Nancy Lee</dc:creator>
                <dc:creator>Laifong Lee</dc:creator>
                <dc:creator>Sandra Dabora</dc:creator>
                <dc:source>BMC Dermatology 2008, 8:1</dc:source>
        <dc:date>2008-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-5945-8-1</dc:identifier>
        <prism:publicationName>BMC Dermatology</prism:publicationName>
        <prism:issn>1471-5945</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2008-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
